Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

Z. Al-Kadhimi, Z. Gul, M. Abidi, L. G. Lum, A. Deol, W. Chen, H. Jang, C. Ozust, A. Langston, E. Waller, J. Uberti

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-Thymocyte globulin (Thymoglobulin Thymo) in combination with tacrolimus and sirolimus (TTS) in 47 patients (pts) for the prevention of acute and chronic GvHD after unrelated AHSCT. The median follow-up was 45.2 months. The cumulative incidence of NIH severe cGvHD at 48 months was 6.4% with no new occurrences past 6 months for the entire follow-up period. The overall cumulative incidence of cGvHD was 44.7%. Out of 20 pts who are alive and disease-free at the last follow-up, only 4 pts continue to need systemic immune suppression. We observed low late NRM with only 3 transplant-related deaths after 6 months post transplant. At 4 years of follow-up, the overall cumulative incidence of NRM and disease relapse was 27.7% and 30.0%, respectively. PFS and overall survival (OS) at 4 years were 42 and 47%. At long term follow-up, TTS was associated with low incidence of severe cGvHD and late NRM.

Original languageEnglish (US)
Pages (from-to)1304-1310
Number of pages7
JournalBone marrow transplantation
Volume52
Issue number9
DOIs
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention'. Together they form a unique fingerprint.

  • Cite this

    Al-Kadhimi, Z., Gul, Z., Abidi, M., Lum, L. G., Deol, A., Chen, W., Jang, H., Ozust, C., Langston, A., Waller, E., & Uberti, J. (2017). Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. Bone marrow transplantation, 52(9), 1304-1310. https://doi.org/10.1038/bmt.2017.95